Month: May 2025

SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions. The Company intends to use the net proceeds from this offering for research and development, general corporate purposes and working capital needs. The offering...

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that it will host a virtual R&D call, titled “Deucrictibant: Beyond HAE Type 1/2” on Wednesday, June 4, at 8:00 a.m. ET/14:00 CET. The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated...

MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V: FPC) (“Falco” or the “Corporation“) is pleased to announce that it has responded to all questions and comments requested by the Direction de l’évaluation environnementale (“DEE“) des projets industriels et miniers on February 27, 2025 (the “Correspondence“), as more fully described in Falco’s press release dated March 3, 2025. The responses, commitments, and explanatory letter submitted (the “Responses“) follow the meetings and clarifications obtained from representatives of the Ministère de l’Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs (the “Ministry“) and other ministries, regarding the principal issues raised by the Horne 5...

New report explores Solana’s rise as the infrastructure layer of next-gen finance Zurich, 12 May 2025 – 21Shares, one of the world’s largest issuers of cryptocurrency exchange-traded products (ETPs), today announced the release of the 14th edition of its flagship research series, State of Crypto, featuring an in-depth spotlight on Solana. With ultra-high speed, near-zero fees, and a rapidly expanding ecosystem, Solana has emerged as a leading blockchain powering everything from cross-border payments to AI and decentralised physical infrastructure. The new report explores Solana’s evolution into a real-world financial layer, and why it is fast becoming the blockchain of choice for both developers and institutions. “Solana is redefining what’s possible with blockchain technology,” said Adrian Fritz, Head of Research at 21Shares. “It combines...

– 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) – – 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) – – Median progression free survival of 5.8 months as of April 7th 2025 data cutoff – – Encouraging initial safety profile with no dose limiting toxicities at data cutoff – – Planning Phase 2 study initiation in 1H 2026 – – Conference call on Monday, May 12 at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced positive interim Phase 1 data for its EpCAM PROBODY® ADC candidate,...

HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the development and operation of high-quality producing energy and industrial gas assets, today reported financial and operating results for the three months ended March 31, 2025. MANAGEMENT COMMENTS “We are pleased with the momentum U.S. Energy has built in the first quarter of 2025 as we execute our strategy to become a leading provider of non-hydrocarbon industrial gases,” said Ryan Smith, Chief Executive Officer of U.S. Energy. “Our Montana development is progressing on schedule, with meaningful advancements across upstream operations, infrastructure planning, and carbon management. These milestones highlight the potential of the Kevin Dome as a unique, low-impact resource...